Mind the target: programmed death ligand 1 in oesophagogastric cancers
| Autor: | Luke A, Wylie, Harriet C, Baker, Elizabeth C, Smyth |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Current Opinion in Oncology. 34:389-394 |
| ISSN: | 1531-703X 1040-8746 |
| DOI: | 10.1097/cco.0000000000000859 |
| Popis: | Metastatic oesophagogastric cancers carry a prognosis of generally less than 2 years despite current treatment. There has been recent excitement in the field focused on immune checkpoint inhibition though anti-PD-1 antibodies. In this article, we review recent phase 3 clinical trials evaluating first line PD-L1 inhibition in metastatic HER-2-negative oesophagogastric cancers and discuss future questions and challenges in the field.Prior studies have shown promise using PD-L1 inhibition as third and fourth line treatment but recent phase 3 clinical trials have shown clear benefit to overall survival as first line treatment. PD-L1 inhibition as monotherapy demonstrated earlier death rates but there are a subset of patients with a long-term durable benefit when compared with chemotherapy. PD-L1 inhibition when combined with chemotherapy showed benefit in overall survival and progression-free survival and is enhanced in subsets of patients with increased PD-L1 expression.Although there are still open questions how best to assess PD-L1 status, these studies provide clear evidence for use of PD-L1 inhibition combined with cytotoxic chemotherapy as first-line treatment in metastatic or unresectable oesophagogastric cancers that express PD-L1. In addition, they lay the groundwork for future studies evaluating PD-1 inhibition in earlier stages of disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|